Notify me when Chubb Ltd files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2022 | 3 | $29.9M | $0 | $0 | GRAB, NU, PTCT | 13F-HR | 03 Feb 2023, 12:09 | |
| Q3 2022 | 3 | $27M | $0 | $0 | GRAB, NU, PTCT | 13F-HR | 04 Nov 2022, 10:02 | |
| Q2 2022 | 3 | $24.8M | $0 | -$285K | -$285K | GRAB, NU, PTCT | 13F-HR | 05 Aug 2022, 09:50 |
| Q1 2022 | 4 | $40.2M | +$17.7M | $0 | +$17.7M | GRAB, NU, PTCT, NEWT | 13F-HR | 06 May 2022, 08:23 |
| Q4 2021 | 2 | $45.6M | +$45.2M | $0 | +$45.2M | GRAB, PTCT | 13F-HR | 04 Feb 2022, 09:44 |
| Q3 2021 | 1 | $304K | $0 | -$27.9M | -$27.9M | PTCT | 13F-HR | 08 Nov 2021, 15:16 |
| Q2 2021 | 3 | $28.2M | +$238K | -$6M | -$5.77M | DCT, PTCT, NEWT | 13F-HR | 05 Aug 2021, 14:29 |
| Q1 2021 | 2 | $35.3M | $0 | -$74.5M | -$74.5M | DCT, PTCT | 13F-HR | 05 May 2021, 10:02 |
| Q4 2020 | 3 | $107M | +$102M | -$446K | +$102M | DCT, SNY, PTCT | 13F-HR | 05 Feb 2021, 16:36 |
| Q3 2020 | 3 | $5.12M | $0 | -$22.7M | -$22.7M | SNY, PHR, PTCT | 13F-HR | 30 Oct 2020, 13:41 |
| Q2 2020 | 4 | $28.1M | +$4.44M | $0 | +$4.44M | SNY, PHR, PTCT, NEWT | 13F-HR | 11 Aug 2020, 11:03 |
| Q1 2020 | 3 | $20.3M | +$3.41K | $0 | +$3.41K | SNY, PTCT, NEWT | 13F-HR | 30 Apr 2020, 09:33 |
| Q4 2019 | 3 | $23.4M | +$4.6K | $0 | +$4.6K | SNY, PTCT, NEWT | 13F-HR | 14 Feb 2020, 11:00 |
| Q3 2019 | 3 | $21.5M | +$3.5K | $0 | +$3.5K | SNY, NEWT, PTCT | 13F-HR | 06 Nov 2019, 11:58 |
| Q2 2019 | 3 | $20.2M | $0 | -$128M | -$128M | SNY, NEWT, PTCT | 13F-HR | 07 Aug 2019, 10:25 |
| Q1 2019 | 12 | $149M | +$10.6K | -$2K | +$8.64K | MRK, SNY, BP, PFE, GSK | 13F-HR | 30 Apr 2019, 11:40 |
| Q4 2018 | 13 | $138M | +$3.01K | -$742K | -$739K | MRK, SNY, PFE, TTE, GSK | 13F-HR | 08 Feb 2019, 10:07 |
| Q3 2018 | 14 | $151M | +$3.27K | -$95.9M | -$95.9M | MRK, SNY, TTE, BP, PFE | 13F-HR | 31 Oct 2018, 11:51 |
| Q2 2018 | 21 | $238M | +$1.42M | $0 | +$1.42M | MS, JPM, ADM, BP, MRK | 13F-HR | 27 Jul 2018, 10:17 |
| Q1 2018 | 20 | $230M | +$224K | $0 | +$224K | MS, JPM, ADM, SNY, AZN | 13F-HR | 01 May 2018, 14:25 |
| Q4 2017 | 19 | $230M | +$9.72K | -$934K | -$924K | MS, JPM, SNY, ADM, AZN | 13F-HR | 26 Jan 2018, 14:08 |
| Q3 2017 | 21 | $229M | $0 | -$12.1M | -$12.1M | MS, SNY, MRK, ADM, JPM | 13F-HR | 27 Oct 2017, 10:18 |
| Q2 2017 | 21 | $235M | +$28.7K | $0 | +$28.7K | MS, SNY, MRK, ADM, JPM | 13F-HR | 28 Jul 2017, 10:28 |
| Q1 2017 | 22 | $232M | +$137 | -$2.08M | -$2.08M | MS, ADM, SNY, MRK, JPM | 13F-HR | 04 May 2017, 08:30 |
| Q4 2016 | 25 | $228M | +$1.02M | -$77.5K | +$942K | MS, ADM, SNY, MRK, JPM | 13F-HR | 14 Feb 2017, 14:48 |
| Q3 2016 | 24 | $221M | +$1.81M | -$22.1M | -$20.3M | ADM, MRK, GSK, SNY, AZN | 13F-HR | 14 Nov 2016, 17:49 |
| Q2 2016 | 27 | $231M | +$2.75M | -$148M | -$145M | ADM, SNY, GSK, MRK, AZN | 13F-HR | 12 Aug 2016, 11:28 |
| Q1 2016 | 38 | $367M | $0 | $0 | SNY, BAC, C, AAL, ADM | 13F-HR | 13 May 2016, 10:35 |